Time to Discontinuation of Second-Generation Antipsychotics Versus Haloperidol and Sulpiride in People With Schizophrenia A Naturalistic, Comparative Study

被引:18
作者
Chan, Hung-Yu [1 ,2 ,3 ]
Pan, Yi-Ju [4 ,5 ]
Chen, Jiahn-Jyh [1 ]
Chen, Chiung-Hsu [1 ]
机构
[1] Taoyuan Psychiat Ctr, Dept Gen Psychiat, 71 Longshou St, Taoyuan 33058, Taiwan
[2] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Psychiat, Taipei, Taiwan
[3] Natl Taiwan Univ, Sch Med, Taipei, Taiwan
[4] Far Eastern Mem Hosp, Dept Psychiat, Taipei, Taiwan
[5] Natl Yang Ming Univ, Sch Med, Dept Publ Hlth, Taipei, Taiwan
关键词
antipsychotics; effectiveness; schizophrenia; time to discontinuation; RISK-FACTORS; 1ST EPISODE; FOLLOW-UP; MEDICATION; NONADHERENCE; RISPERIDONE; OLANZAPINE; EFFICACY; CLOZAPINE; RELAPSE;
D O I
10.1097/JCP.0000000000000623
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: A retrospective study was conducted to evaluate the time to discontinuation (TTD) of the first-(FGAs) and second-generation antipsychotics (SGAs). Methods: In total, 918 treatment episodes of patients with schizophrenia, initiated on one of the investigated drugs on an outpatient basis during 2004-2006, were entered into the study. The primary outcome was the duration of the investigated treatment episode. Discontinuation was defined when either patients were admitted or the investigated drug had been stopped for more than 28 days. We used the Cox proportional hazard model to compare hazards of discontinuations among 8 SGAs versus 2 FGAs (haloperidol and sulpiride). The follow-up period was up to 18 months. Results: During the follow-up period, clozapine had the highest rate of continuous treatment in the primary analysis: clozapine, 40.6%; olanzapine, 23.4%; aripiprazole, 22.9%; amisulpride, 21.9%; zotepine, 21.3%; sulpiride, 17.0%; risperidone, 12.8%; quetiapine, 12.5%; haloperidol, 10.6%; and ziprasidone, 10.4%. Compared with haloperidol, 5 SGAs had significantly longer TTD (adjusted hazard ratios and 95% confidence intervals): clozapine (0.403, 0.267-0.607), olanzapine (0.611, 0.439-0.849), aripiprazole (0.570, 0.407-0.795), amisulpride (0.680, 0.487-0.947), and zotepine (0.687, 0.497-0.948), but only clozapine had significantly longer TTD compared with sulpiride (0.519, 0.342-0.786). The sensitivity analysis showed similar results. Implications/Conclusions: The current findings suggested that SGAs or FGAs are not homogeneous groups. Clozapine has the highest rate of continuous treatment among SGAs, and haloperidol is not the representative drug for all FGAs. Furthermore, antipsychotics dropout rate is high in naturalistic situation. A good service model needs to be constructed to enhance antipsychotic treatment adherence of people with schizophrenia.
引用
收藏
页码:13 / 20
页数:8
相关论文
共 50 条
[21]   Impact of Second-Generation Antipsychotics and Perphenazine on Depressive Symptoms in a Randomized Trial of Treatment for Chronic Schizophrenia [J].
Addington, Donald E. ;
Mohamed, Somaia ;
Rosenheck, Robert A. ;
Davis, Sonia M. ;
Stroup, Thomas Scott ;
McEvoy, Joseph P. ;
Swartz, Marvin S. ;
Lieberman, Jeffrey A. .
JOURNAL OF CLINICAL PSYCHIATRY, 2011, 72 (01) :75-80
[22]   Effectiveness of second-generation antipsychotics with acute-phase schizophrenia [J].
Hatta, Kotaro ;
Sato, Koji ;
Hamakawa, Hiroshi ;
Takebayashi, Hiroshi ;
Kimura, Naoto ;
Ochi, Shinichiro ;
Sudo, Yasuhiko ;
Asukai, Nozomu ;
Nakamura, Hiroyuki ;
Usui, Chie ;
Kawabata, Toshitaka ;
Hirata, Toyoaki ;
Sawa, Yutaka .
SCHIZOPHRENIA RESEARCH, 2009, 113 (01) :49-55
[23]   New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia [J].
Citrome, Leslie .
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (07) :767-783
[24]   Cerebral Computed Tomographic Findings in Schizophrenia: Relationship to Second-Generation Antipsychotics and Hyperprolactinemia [J].
Petric, Paula Simina ;
Ifteni, Petru ;
Popa, Andreea Violeta ;
Teodorescu, Andreea .
HEALTHCARE, 2024, 12 (13)
[25]   Pharmacogenetics and Schizophrenia-Can Genomics Improve the Treatment with Second-Generation Antipsychotics? [J].
Plaza, Olga ;
Galecki, Piotr ;
Orzechowska, Agata ;
Galecka, Malgorzata ;
Sobolewska-Nowak, Justyna ;
Szulc, Agata .
BIOMEDICINES, 2022, 10 (12)
[26]   Second-generation antipsychotics and adiponectin levels in schizophrenia: A comparative meta-analysis [J].
Bartoli, Francesco ;
Crocamo, Cristina ;
Clerici, Massimo ;
Carra, Giuseppe .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 (10) :1767-1774
[27]   Time-to-First Discontinuation, Adherence and Persistence in New Users of Second-Generation Antipsychotics [J].
Ndukwe, Henry C. ;
Nishtala, Prasad S. .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2016, 36 (06) :649-657
[28]   Effects of Lithium Combined with Second-Generation Antipsychotics for the Treatment of Manic Episodes in Patients with Bipolar Disorder: A Naturalistic Study in China [J].
Liu, Yang ;
Liang, Jun ;
Xia, Qingrong ;
Zhou, Xin ;
Xie, Xuefeng .
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2020, 16 :2623-2632
[29]   Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder [J].
Vincenzi, Brenda ;
Greene, Claire M. ;
Ulloa, Melissa ;
Parnarouskis, Lindsey ;
Jackson, John W. ;
Henderson, David C. .
JOURNAL OF PSYCHIATRIC PRACTICE, 2016, 22 (03) :175-182
[30]   Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis [J].
Leucht, Stefan ;
Corves, Caroline ;
Arbter, Dieter ;
Engel, Rolf R. ;
Li, Chunbo ;
Davis, John M. .
LANCET, 2009, 373 (9657) :31-41